These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38105401)

  • 1. PCSK9: an emerging player in cardiometabolic aging and its potential as a therapeutic target and biomarker.
    Csiszar A; Tarantini S; Yabluchanskiy A; Ungvari Z
    Geroscience; 2024 Feb; 46(1):257-263. PubMed ID: 38105401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside.
    Bao X; Liang Y; Chang H; Cai T; Feng B; Gordon K; Zhu Y; Shi H; He Y; Xie L
    Signal Transduct Target Ther; 2024 Jan; 9(1):13. PubMed ID: 38185721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system.
    Bell AS; Wagner J; Rosoff DB; Lohoff FW
    Neurosci Biobehav Rev; 2023 Jun; 149():105155. PubMed ID: 37019248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond.
    Grewal T; Buechler C
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9: a key modulator of cardiovascular health.
    Seidah NG; Awan Z; Chrétien M; Mbikay M
    Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypercholesterolemia: The role of PCSK9.
    Melendez QM; Krishnaji ST; Wooten CJ; Lopez D
    Arch Biochem Biophys; 2017 Jul; 625-626():39-53. PubMed ID: 28587771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles.
    Sarkar SK; Foo ACY; Matyas A; Asikhia I; Kosenko T; Goto NK; Vergara-Jaque A; Lagace TA
    J Biol Chem; 2020 Feb; 295(8):2285-2298. PubMed ID: 31949048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype.
    Chorba JS; Galvan AM; Shokat KM
    J Biol Chem; 2018 Feb; 293(6):1875-1886. PubMed ID: 29259136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
    Lu X
    Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
    Guo S; Xia XD; Gu HM; Zhang DW
    Adv Exp Med Biol; 2020; 1276():137-156. PubMed ID: 32705598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
    Banerjee Y; Santos RD; Al-Rasadi K; Rizzo M
    Atherosclerosis; 2016 May; 248():62-75. PubMed ID: 26987067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9: from biology to clinical applications.
    Blanchard V; Khantalin I; Ramin-Mangata S; Chémello K; Nativel B; Lambert G
    Pathology; 2019 Feb; 51(2):177-183. PubMed ID: 30522786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.
    Lagace TA
    Curr Opin Lipidol; 2014 Oct; 25(5):387-93. PubMed ID: 25110901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics.
    Gauthier MS; Awan Z; Bouchard A; Champagne J; Tessier S; Faubert D; Chabot K; Garneau PY; Rabasa-Lhoret R; Seidah NG; Ridker PM; Genest J; Coulombe B
    J Clin Lipidol; 2018; 12(4):1027-1038. PubMed ID: 29699916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibiting PCSK9 - biology beyond LDL control.
    Stoekenbroek RM; Lambert G; Cariou B; Hovingh GK
    Nat Rev Endocrinol; 2018 Dec; 15(1):52-62. PubMed ID: 30367179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of natural products as PCSK9 modulators: A review.
    Khayatan D; Zare K; Khanahmadi M; Momtaz S; Butler AE; Jamialahmadi T; Almahmeed W; Abdolghaffari AH; Sahebkar A
    Phytother Res; 2024 Aug; 38(8):4081-4098. PubMed ID: 38899632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.